mTOR immunosuppression in HIV-positive liver transplant recipients

On the basis of our experience, we would suggest that control of HIV-RNA viremia in liver transplanted patients is still a matter of the choice of the best ART independently from the type of the antirejection treatment; moreover, the use of rapamycin in this context may bemisleading because it has been already clearly
demonstrated that ART has an impact on overall survival in HIV-positive liver transplanted patients.